Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zontivity (vorapaxar) for the Reduction of Thrombotic Cardiovascular Events

Drug Name (Brand / Generic)

Zontivity / vorapaxar

Company / Licensee

Schering-Plough / Merck

Therapy Class

Protease-activated receptor-1 (PAR-1) antagonist

Current Indication

Reduction of thrombotic cardiovascular events in patients with a history of heart attack or peripheral arterial disease (PAD)

Market Sector

Cardiovascular

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top